|
|
Office Locations:
|
888 Boylston Street, Suite 1111
Boston, MA 02199
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
Omega Funds was established in 2004, and manages six funds with investments across Europe, North America and the Far East. Omega invests in both public and private companies, completing investments across all healthcare sectors, including biotech, medtech, diagnostics, services and healthcare IT since inception. The firm considers investments in three areas: Primary Venture - Investing in early-, mid- and late-stage private companies developing transformational technologies and products to address unmet needs in healthcare and biotechnology; Publics - Supporting the capital needs of publicly traded, small-cap life sciences companies with short or medium term clinical milestones, usually via PIPEs or IPOs; and Direct Secondaries - Providing partial or total liquidity as well as follow-on capital, to existing shareholders in single assets or portfolios of companies. Investments have led to 37 new products, many charting new treatment courses for patients with devastating diseases such as acute lymphoblastic leukemia, melanoma, and Huntington’s disease, among many others.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
